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Articles
Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous 
meningitis in HIV-infected adults: a prospective cohort study
Nathan C Bahr, Edwin Nuwagira, Emily E Evans, Fiona V Cresswell, Philip V Bystrom, Adolf Byamukama, Sarah C Bridge, Ananta S Bangdiwala, 
David B Meya, Claudia M Denkinger, Conrad Muzoora, David R Boulware, on behalf of the ASTRO-CM Trial Team
Summary 
Background WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous meningitis. However, 
diagnosis remains difficult, with Xpert sensitivity of about 50–70% and culture sensitivity of about 60%. We evaluated 
the diagnostic performance of the new Xpert MTB/RIF Ultra (Xpert Ultra) for tuberculous meningitis.
Methods We prospectively obtained diagnostic cerebrospinal fluid (CSF) specimens during screening for a trial on 
the treatment of HIV-associated cryptococcal meningitis in Mbarara, Uganda. HIV-infected adults with suspected 
meningitis (eg, headache, nuchal rigidity, altered mental status) were screened consecutively at Mbarara Regional 
Referral Hospital. We centrifuged CSF, resuspended the pellet in 2 mL of CSF, and tested 0·5 mL with mycobacteria 
growth indicator tube culture, 1 mL with Xpert, and cryopreserved 0·5 mL, later tested with Xpert Ultra. We assessed 
diagnostic performance against uniform clinical case definition or a composite reference standard of any positive 
CSF tuberculous test.
Findings From Feb 27, 2015, to Nov 7, 2016, we prospectively evaluated 129 HIV-infected adults with suspected 
meningitis for tuberculosis. 23 participants were classified as probable or definite tuberculous meningitis by uniform 
case definition, excluding Xpert Ultra results. Xpert Ultra sensitivity was 70% (95% CI 47–87; 16 of 23 cases) for 
probable or definite tuberculous meningitis compared with 43% (23–66; 10/23) for Xpert and 43% (23–66; 10/23) for 
culture. With composite standard, we detected tuberculous meningitis in 22 (17%) of 129 participants. Xpert Ultra 
had 95% sensitivity (95% CI 77–99; 21 of 22 cases) for tuberculous meningitis, which was higher than either Xpert 
(45% [24–68]; 10/22; p=0·0010) or culture (45% [24–68]; 10/22; p=0·0034). Of 21 participants positive by Xpert Ultra, 
13 were positive by culture, Xpert, or both, and eight were only positive by Xpert Ultra. Of those eight, three were 
categorised as probable tuberculous meningitis, three as possible tuberculous meningitis, and two as not tuberculous 
meningitis. Testing 6 mL or more of CSF was associated with more frequent detection of tuberculosis than with less 
than 6 mL (26% vs 7%; p=0·014).
Interpretation Xpert Ultra detected significantly more tuberculous meningitis than did either Xpert or culture. WHO 
now recommends the use of Xpert Ultra as the initial diagnostic test for suspected tuberculous meningitis.
Funding National Institute of Neurologic Diseases and Stroke, Fogarty International Center, National Institute of 
Allergy and Infectious Disease, UK Medical Research Council/DfID/Wellcome Trust Global Health Trials, Doris 
Duke Charitable Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Tuberculous meningitis is the second most common 
cause of adult meningitis in Africa.1–4 Meningitis from 
tuberculosis leads to fatality in more than 50% of cases, 
in large part due to difficulty and delay in diagnosis.5 
Cerebrospinal fluid (CSF) smear microscopy for acid-fast 
bacilli has poor sensitivity (≤15%) in routine care.5 
Although mycobacterial culture has higher sensitivity 
(50–60%), culture is too slow to be clinically useful.5
In 2013, WHO endorsed the Xpert MTB/RIF assay 
(Cepheid, Sunnyvale, CA, USA) as the preferred initial test 
to investigate tuberculous meningitis after a systematic 
review of 13 studies.6–8 The Xpert is cartridge-based fully-
automated PCR test. Of three large cohorts, the first 
reported 67% sensitivity using Xpert in microbiologically 
proven tuberculous meningitis in HIV-infected South 
Africans.9 This study initially tested 1 mL of CSF but later 
found higher sensitivity (82%; 22 of 27 positive cases) 
when centrifuging 3 mL of CSF.9 Sensitivity compared 
with consensus clinical case definition was only 36%.9,10 
The second large cohort study, in Vietnam, measured 
Xpert against the same clinical case definition and found 
59% sensitivity generally using 2 mL or less of centrifuged 
CSF.11,12 A third Ugandan study reported 28% sensitivity 
with 2 mL of uncentrifuged CSF and 72% sensitivity when 
centrifuging a median volume of 6 mL (IQR 4–10) with 
Xpert.12 Thus, the imperfect sensitivity has meant no test 
can exclude tuberculous meningitis.13,14
The Xpert MTB/RIF Ultra (Xpert Ultra) is a new, fully 
automated, nested real-time PCR assay for the GeneXpert 
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platform. The re-engineered Xpert Ultra has sought to 
improve the analytical sensitivity for Mycobacterium 
tuberculosis detection and to improve rifampin resistance 
detection.15 We analysed the diagnostic performance of 
Xpert Ultra for detection of M tuberculosis in CSF as 
compared with Xpert or culture. We hypothesised that 
Xpert Ultra would have improved sensitivity. Preliminary 
results of Xpert Ultra performance were summarised in 
a WHO report in March, 2017.16
Methods
Study design and participants
We prospectively obtained diagnostic CSF specimens 
during screening for the Adjunctive Sertraline for the 
Treatment of HIV-associated Cryptococcal Meningitis 
trial (NCT01802385). HIV-infected adults with suspected 
meningitis (eg, headache, nuchal rigidity, altered mental 
status) were screened consecutively at Mbarara Regional 
Referral Hospital in Mbarara, Uganda. Clinical history, 
general examination, and detailed neurological findings 
were prospectively recorded, in agreement with the data 
considered important by Marais and colleagues17 for 
tuberculous meningitis studies. Further investigations, 
including chest radiography, abdominal ultrasonography, 
and sputum Xpert MTB/RIF, were undertaken as 
clinically indicated. Brain imaging was unavailable. 
Processing of CSF samples is described in the appendix 
(p 7). Eligible participants were at least 18 years of age 
with suspected meningitis. All participants or their 
surrogates provided written informed consent, including 
for additional future diagnostic testing. Institutional 
review board approvals occurred.
Procedures
After lumbar puncture, physicians did cryptococcal 
antigen lateral flow assay (IMMY, Norman, OK, USA) 
testing at the bedside. All participants without 
cryptococcosis were then evaluated for tuberculous and 
bacterial meningitis; this stepwise diagnostic approach 
was a deliberate cost-efficient approach.1 Participants 
with cryptococcal meningitis with concern of tuberculous 
meningitis co-infection were included at physician 
discretion.
The algorithm for CSF diagnostic testing is fully 
described in the appendix (p 7). After bedside testing, 
approximately 1 mL of CSF was removed for routine 
testing (eg, white cell count, protein, glucose, Gram 
stain, Ziehl-Neelsen stain), and we centrifuged the 
Research in context
Evidence before this study
The Xpert MTB/RIF (Xpert) Ultra is a new assay without prior 
publications. We searched PubMed with the terms 
((tuberculous meningitis) or TB meningitis) AND (Xpert 
MTB/RIF Ultra) for articles published in English up to 
June 19, 2017, which yielded no results. We also searched 
Google Scholar for articles related to Xpert Ultra, which yielded 
one conference abstract, which had been cited by 
13 publications relating to the future of tuberculosis diagnostics 
but without including any data on Xpert Ultra. When we 
searched PubMed with the terms (Tuberculous meningitis) or 
TB meningitis) AND (Xpert MTB/RIF), we found and reviewed 
21 publications. These publications reported imperfect 
sensitivity of cerebrospinal fluid Xpert, ranging from 50% to 
72% against cerebrospinal fluid Mycobacterium tuberculosis 
culture. A meta-analysis reported that Xpert has a pooled 
sensitivity of 80·5% against culture and 62·8% against a clinical 
reference standard. Three opinion pieces point out that with 
imperfect sensitivity, the Xpert assay cannot be used as a 
rule-out test for tuberculous meningitis and an assay with 
improved diagnostic performance is urgently needed.
Added value of this study
To our knowledge, we present the first evaluation of the 
diagnostic performance of Xpert Ultra in the diagnosis of 
tuberculous meningitis. Xpert Ultra has been re-engineered to 
improve diagnostic performance with a lower analytic limit of 
detection, comparable to mycobacterial culture. We assessed 
diagnostic performance in two ways. First, against any positive 
cerebrospinal fluid tuberculosis test being defined as definite 
tuberculosis, and second, against a consensus clinical case 
definition not including the Xpert Ultra result. Xpert Ultra had 
higher sensitivity of 95% than either Xpert (45%) or culture (45%) 
for definite tuberculous meningitis. Based on the consensus 
clinical case definition, Xpert Ultra found 70% sensitivity for 
probable or definite tuberculous meningitis. Xpert or culture each 
had 43% sensitivity for probable or definite tuberculosis based on 
the clinical case definition (which excluded Xpert Ultra results).
Implications of all the available evidence
A diagnostic test exhibiting more than 90% sensitivity for 
tuberculous meningitis with results available in fewer than 
90 min holds great potential to improve patient outcomes, 
particularly to detect those with the lowest bacillary load. The 
negative predictive value of 99% against definite tuberculous 
meningitis is a major step forward in tuberculous meningitis 
diagnostics. However, negative predictive value was only 
93% against probable or definite tuberculous meningitis, and 
thus clinical judgment remains paramount. Xpert Ultra’s 
combination of lower analytic limit of detection and ability to 
detect dead bacilli after starting tuberculosis therapy vastly 
improves sensitivity compared with either culture or Xpert. 
On the basis of our findings, we believe Xpert Ultra should be a 
first-line test for tuberculous meningitis after excluding 
cryptococcal infection. The assay must now be evaluated 
prospectively in a larger study including in HIV-negative 
individuals and children, and in which post-mortem evidence 
of tuberculosis can be included in a reference standard.
See Online for appendix
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remaining volume at 3000 × g for 20 min. We removed 
and cryopreserved all supernatant except for 2 mL, which 
we resuspended via vortexing for 15–20 s. We then used 
1 mL for Xpert testing, 0·5 mL for tuberculous culture, 
and 0·5 mL for storage at −80˚C awaiting Xpert Ultra 
availability. Xpert testing was done with 1 mL sample 
reagent. We did cultures using mycobacteria growth 
indicator tube (MGIT) with a Bactec960 instrument 
(Becton Dickinson, Franklin Lakes, NJ, USA) at the 
Médecins Sans Frontières Epicentre Mbarara laboratory. 
When Xpert Ultra became available, 0·5 mL of 
cryopreserved CSF was thawed, 1·5 mL of sample 
reagent added, and the mixture immediately pipetted 
into the Xpert Ultra cartridge and run. All CSF testing 
was prospective except for Xpert Ultra, which we did on 
cryopreserved samples, albeit planned prospectively. 
Positive values for all tests were per manufacturer 
protocols. Clinical data and other test results were 
unavailable to those performing each separate 
tuberculous test.
We assessed diagnostic performance of Xpert Ultra in 
two ways. First, we used the uniform clinical case 
definition as described by Marais and colleagues.10 We 
categorised participants as definite, probable, possible, 
and not tuberculous meningitis. We defined definite 
tuberculous meningitis in accordance with the consensus 
definition as any CSF test positivity by microscopy, 
culture, or commercialised PCR (including Xpert or 
Xpert Ultra).10 The definition for definite tuberculous 
meningitis included PCR testing because culture is an 
insensitive tuberculous meningitis reference standard,10 
and we judged the likelihood of tuberculous DNA 
detection in the CSF of an HIV-infected person with 
aseptic meningitis representing a false positive result as 
low (eg, M tuberculosis colonisation in the CSF is 
extremely unlikely and, given the clinical context, a rare 
lab contamination is less likely than a PCR test indicating 
true tuberculous meningitis).7 We included the fully 
automated PCR Xpert Ultra test in this composite 
reference standard with the recognition that, in vitro, its 
analytical sensitivity is ten times greater than that of 
Xpert.15 This inclusion was prespecified but risks an 
incorporation bias. Thus, we did a second analysis that 
did not include Xpert Ultra results as part of the Marais 
reference standard.10
We did additional molecular testing to exclude 
alternative aetiologies and confirm Xpert Ultra results. 
First, we retrospectively ran CSF specimens positive only 
for Xpert Ultra on the FilmArray Meningitis/Encephalitis 
Panel (BioFire Diagnostics, Salt Lake City, UT, USA), 
which uses a multiplex PCR to detect nucleic acids of 
14 meningitis pathogens of Streptococcus pneumoniae, 
Neisseria meningitidis, Listeria monocytogenes, Haemophilus 
influenzae, Streptococcus agalactiae, Escherichia coli, 
herpes simplex virus types 1 and 2, cytomegalovirus, 
varicella zoster virus, human herpes virus 6, enterovirus, 
human parechovirus, and Cryptococcus neoformans/gattii.18
Second, we used next-generation sequencing to verify 
the presence of M tuberculosis DNA by an alternative 
method. For CSF specimens positive for Xpert Ultra, we 
extracted the residual volume of liquid left in the Xpert 
Ultra cartridges, which potentially contained DNA 
amplicons, and deep sequenced it on an Illumina 
MiniSeq platform (Illumina, San Diego, CA, USA).19 
DNA sequencing methodology is further described in 
the appendix (p 5).
Statistical analysis
We calculated sensitivity, specificity, negative predictive 
value, and positive predictive value by defining true or false 
positives and true or false negatives against the reference 
standard with inclusion or with exclusion of Xpert Ultra 
results. We used SPSS version 24 (IBM, Armonk, NY, 
USA) to compare baseline clinical characteristics and 
demographic data by diagnosis via Mann-Whitney U for 
continuous variables and Fisher’s exact test for categorical 
variables. We evaluated concordance between diagnostic 
assays with McNemar’s test. We counted invalid tests (eg, 
culture contamination, Xpert error) as negative results.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
129 eligible and tested with Xpert Ultra
221 potentially eligible participants screened
108 Xpert Ultra negative 21 Xpert Ultra positive
92 excluded (CSF cryptococcal
antigen positive)
21 diagnosed with tuberculosis
meningitis with composite
reference standard
1 positive with composite
reference standard
107 negative with composite
reference standard
Final diagnosis:
  16 Cyptococcus neoformans
  2 Streptococcus pneumoniae
  79 lymphocytic, unknown 
   pathogen
  10 non-inflammatory*
Final diagnosis:
1 Myobacterium tuberculosis 
Final diagnosis:
21 Myobacterium tuberculosis
Figure 1: Trial profile
Composite reference standard was culture, Xpert, or Xpert Ultra. CSF=cerebrospinal fluid. Xpert=Xpert MTB/RIF. 
*Suspected meningitis with normal cerebrospinal fluid profile of <5 leucocytes per µL and protein <40 mg/dL.
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Results
Of 221 HIV-infected people presenting with suspected 
meningitis between Feb 27, 2015, and Nov 7, 2016, 
129 participants underwent tuberculous testing with Xpert, 
culture, and Xpert Ultra on centrifuged CSF (figure 1). Of 
these, 113 had a negative CSF cryptococcal antigen and 16 
had a positive cryptococcal antigen but had tuberculous 
meningitis testing at physician discretion out of clinical 
suspicion. A median of 8 mL (IQR 5–11) of CSF was 
collected and centrifuged. We diagnosed definite 
tuberculous meningitis in 22 (17%) of 129 participants 
tested per the prespecified composite reference standard 
of any microbiological CSF test positivity (n=10 Xpert; 
n=10 culture; n=21 Xpert Ultra; figure 2). Participant 
characteristics of those with and without tuberculous 
meningitis did not differ aside from lower CSF glucose, 
higher CSF protein, and a higher proportion with prior 
tuberculosis among those diagnosed with tuberculous 
meningitis (table 1).
One participant with definite tuberculous meningitis 
was positive by culture and negative by Xpert and Xpert 
Ultra (table 2). Of the eight cases detected only by Xpert 
Ultra, one was receiving antituberculous therapy and 
six were receiving HIV therapy. The eight cases were 
also negative for all 14 pathogens on the FilmArray 
Meningitis/Encephalitis Panel and cryptococcal antigen. 
Overall, 11 of 22 participants with tuberculous meningitis 
died during hospitalisation, two were known to have died 
after discharge, and one was lost to follow-up (table 2).
We assessed diagnostic performance for Xpert Ultra, 
Xpert, and culture compared with microbiologically 
proven, definite tuberculous meningitis positive by any 
of the three methods and with the uniform clinical case 
definition for definite or probable tuberculous 
meningitis (table 3). Xpert Ultra produced a sensitivity 
of 95% (21 of 22 positive cases) for microbiologically 
proven, definite tuberculous meningitis, which was 
superior to either Xpert (45%; ten of 22; p=0·0010) or 
culture (45%; ten of 22; p=0·0034; table 3). The negative 
predictive value for a negative Xpert Ultra was 99% (106 
of 107 negative cases) in excluding microbiologically 
proven tuberculous meningitis. Conversely, the negative 
predictive value was 90% (107 of 119 negative cases) for 
both Xpert and culture. The time to positive 
mycobacteria culture was a median of 16 days 
(IQR 14–23). Among ten people with positive CSF 
cultures, seven died before cultures grew, with the 
median time to culture positivity being 17 days (IQR 
13–21, range 9–43) after death. By comparison, the Xpert 
Ultra assay run time was 83 min.
Next-generation sequencing was done on seven Xpert 
Ultra positive cartridges (selected owing to availability). 
Six cartridges had a sufficient residual volume present 
inside the cartridge to successfully extract DNA and 
identify M tuberculosis genes by next-generation sequencing 
(table 4). Of these six cartridges, two had been only positive 
by Xpert Ultra (table 4). The seventh cartridge had a 
residual volume of less than 5 µL present after storage, 
resulting in unsuccessful sequencing (table 4).
We also classifed participants on the basis of the 
consensus uniform case definitions for tuberculous 
meningitis (appendix pp 2–5).10 When excluding Xpert 
Ultra results in the classification of definite tuberculous 
meningitis (to avoid incorporation bias), we diagnosed 
only 14 participants with definite tuberculous meningitis, 
 Xpert Ultra 
 MGIT culture Xpert 
 
 
8 
 
4 3
6 
 
  
0 
   0 1
 
 
107 participants negative for tuberculosis
Figure 2: Venn diagram of overlap in tuberculous meningitis diagnostics
 The Venn diagram displays 22 participants with tuberculosis detected in CSF by 
each diagnostic test and the overlap between tests. Of eight participants positive 
by Xpert Ultra only, six had recently initiated HIV therapy, and all eight were 
negative by testing with cryptococcal antigen, India ink, Gram stain, culture, and 
multiplex PCR for 14 common meningitis pathogens. Xpert=Xpert MTB/RIF. 
MGIT=mycobacteria growth indicator tube. CSF=cerebrospinal fluid. 
Tuberculous meningitis, 
composite definition 
(n=22)
Other meningitis 
(n=107)
p value
Age, years 32 (30–34) 34 (29–43) 0·24
Men 13 (59%) 58 (54%) 0·82
Women 9 (41%) 49 (46%) 0·82
Headache duration, days 7·0 (6·5–14·0) 4·5 (7·0–14·0) 0·83
CD4 T-cell count, cells per µL 72 (43–124) 73 (16–214) 0·92
Serum C-reactive protein, mg/L 49 (11–78) 49 (11–108) 0·86
CSF white blood cells per μL 12 (3–140) 4 (2–15) 0·12
CSF lymphocytes, % 70% (65–85) 70% (62–79) 0·32
CSF total protein, mg/dL 300 (100–565) 170 (53–355) 0·014
CSF glucose, mg/dL 44 (27–65) 69 (49–93) 0·0020
Prior tuberculosis diagnosis 4 (18%) 3 (3%) 0·016
Physician tuberculous meningitis 
diagnosis*
13 (59%) 45 (42%) 0·24
Alive at discharge or last contact 11 (50%) 75/103 (73%)† 0·045
Data are median (IQR) or n (%).Tuberculous meningitis is defined by composite definition including any positive PCR or 
culture result. CSF=cerebrospinal fluid. *Final hospital diagnosis without incorporating any delayed culture results, 
owing to incubation of up to 8 weeks. †Four patients left against medical advice, with unknown outcome.
Table 1: Participant characteristics
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and classified nine as probable (ie, total diagnostic score 
of ≥10, with ≥2 points coming from CSF criteria). We 
classified 56 participants as having possible tuberculous 
meningitis (total diagnostic score of 6–9 points). 
50 participants were classified as not having tuberculous 
meningitis as defined by a known alternative diagnosis 
of cryptococcal meningitis (n=16) or Streptococcus 
pneumoniae meningitis (n=2); or with no convincing 
evidence of tuberculous meningitis (eg, score <6 points, 
no alternative diagnosis; n=32).
We compared Xpert Ultra testing of CSF to the 
uniform clinical case definition categories of probable or 
definite tuberculous meningitis wherein Xpert Ultra 
results were excluded (table 3). Culture and Xpert shared 
the same sensitivity for probable or definite tuberculous 
meningitis (table 3). For Xpert Ultra, we found higher 
sensitivity compared with Xpert or culture (table 3) and a 
negative predictive value of 93% (100 of 107 negative 
cases). If one assumed Xpert Ultra detection of M 
tuberculosis DNA in CSF represents false positivity in a 
person living with AIDS (which we believe is 
improbable), the diagnostic specificity was 95% (101 of 
106 negative cases) among possible or non-tuberculous 
meningitis. Of these five putative Xpert Ultra false 
positives, four died and one was lost to follow-up 
(presumed dead). However, we believe these are not 
false positives. Among the three other participants with 
probable tuberculous meningitis that were positive by 
Ultra only, two participants received empirical therapy, 
one of whom survived (table 2).
Xpert Ultra results include semi-quantitative categories 
of trace, very low, low, moderate, and high. Of 21 Xpert 
Ultra positive specimens, nine (43%) were trace, seven 
(33%) were very low, and five (24%) were low (table 2). Of 
the eight samples that were positive only by Xpert Ultra, 
six (75%) were trace and two (25%) were very low. Overall, 
the median CD4 of participants according to category 
was 36 cells per µL (IQR 16–61) for trace, 85 cells per µL 
(72–133) for very low, and 73 cells per µL (61–124) for low.
Rifampin resistance by Xpert Ultra testing was not 
detected in 13 cases, and nine cases were indeterminate, 
all of which had trace quantification. No discordance 
occurred with resistance testing by Xpert or culture.
CSF collection volume remained important. Among 
participants without cryptococcal meningitis (who require 
large volume lumbar punctures for control of intracranial 
pressure), testing of at least 6 mL of CSF (median 10 mL 
[IQR 8–12]) was associated with a tuberculous meningitis 
diagnosis (19 [26%] of 73) compared with less than 6 mL 
(4 mL [3–5mL]; 3 [7%] of 43; p=0·014)].
Discussion
In this HIV-infected cohort, Xpert Ultra testing 
demonstrated greater sensitivity when compared with 
culture or Xpert for tuberculous meningitis diagnosis. 
Xpert Ultra showed 95% sensitivity compared with 45% 
sensitivity for Xpert or MGIT culture. Importantly, of the 
21 cases detected by Xpert Ultra, eight (38%) were not 
detected by Xpert or MGIT culture. One person was 
detected only by culture. Of the eight cases detected only 
by Ultra, case definitions categorised three as probable 
tuberculous meningitis, three as possible, and two as 
non-tuberculous meningitis. Importantly, most patients 
did not have imaging outside of the CNS completed and 
none had CNS imaging completed. Imaging might have 
pushed the two non-tuberculous cases into the possible 
tuberculous meningitis category, but also reflect the 
possible limitations of a clinical case definition. 
Alternatively, these tuberculous meningitis cases might 
be of a different phenotype from that which is typically 
detected or—although less likely—the results might be 
falsely positive. Although the examination of CSF 
specimens by Xpert Ultra was from cryopreserved 
samples, this study represents a potentially large step 
forward in the diagnosis of tuberculous meningitis.
A diagnostic test exhibiting greater than 90% sensitivity 
for tuberculous meningitis with results available in less 
than 90 min holds great potential to improve patient 
outcomes, particularly in detecting those with the lowest 
burden of infection. Further, a major concern in using 
the original Xpert for diagnosing tuberculous meningitis 
was an inadequate negative predictive value to rule out 
tuberculous meningitis.13,14 The improved negative 
predictive value found with Xpert Ultra would constitute 
Sensitivity vs composite 
endpoint (95% CI; n/N)
Sensitivity vs case definition 
(95% CI; n/N)
Assay error rate
Xpert Ultra 95% (77–99; 21/22) 70% (47–87; 16/23) 2·3% (3/129)
Xpert 45% (24–68; 10/22) 43% (23–66; 10/23) 4·7% (6/129)
MGIT culture 45% (24–68; 10/22) 43% (23–66; 10/23) 1·6% (2/129)
All three tests were done in all 129 participants. Composite endpoint included any positive CSF Xpert Ultra, Xpert, 
or Bactec960 MGIT culture. Sensitivity vs uniform clinical case definition for definite (n=14) or probable (n=9) 
tuberculous meningitis excluded Xpert Ultra results in defining case status.10 Error in culture reflects contamination 
with non-tuberculous mycobacterium growth. Xpert=Xpert MTB/RIF. MGIT=mycobacteria growth indicator tube. 
CSF=cerebrospinal fluid. 
Table 3: CSF diagnostic performance for tuberculous meningitis of Xpert, culture, and Xpert Ultra
Xpert Ultra 
category
MGIT culture Xpert Next-generation sequencing
of M tuberculosis genes
5001 Trace Negative Negative IS6110 detected
5004 Very low Positive Positive IS6110, IS1081, rpoB (WT) detected
5005 Trace Positive Negative Negative* 
5103 Trace Positive Negative IS6110 detected
5194 Very low Positive Positive IS6110, IS1081, rpoB (WT) detected
5116 Trace Negative Negative IS6110 detected
5285 Very low Negative Positive IS6110, IS1081, rpoB (WT) detected
Data presented for the seven participants, listed by participant ID, whose cartridges were available for testing. All other 
cartridges were promptly discarded per standard infection control procedures. IS6110 and IS1081 are insertion 
elements found exclusively with M tuberculosis complex. rpoB is the β subunit of RNA polymerase gene. Xpert=Xpert 
MTB/RIF. MGIT=mycobacteria growth indicator tube. WT=wild type without rifampin resistance. *<5 µL available for 
testing.
Table 4: Next-generation sequencing results of Mycobacterium tuberculosis DNA
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a major improvement. However, the negative predictive 
value was 99% against definite tuberculous meningitis 
but was only 93% against probable or definite tuberculous 
meningitis. Thus, clinical judgment remains paramount, 
and for this Xpert Ultra cannot substitute.
Tuberculous meningitis is a paucibacillary disease.20 
Thus, any diagnostic assay seeking to microbiologically 
detect tuberculous meningitis must optimise the limit of 
detection while maintaining specificity. MGIT culture 
has an analytical sensitivity threshold of about ten bacilli 
(colony-forming units [CFU] per mL) whereas Xpert has 
a threshold of about 100 CFU/mL.9,21 Xpert Ultra has a 
limit of detection of about 10 CFU/mL,15 which probably 
explains the improved sensitivity of Xpert Ultra as 
compared with Xpert. Re-engineering of the Ultra 
cartridge allows double the volume of DNA to reach the 
PCR reaction. However, the volumes of centrifuged CSF 
available for this study (1·0 mL for Xpert and 0·5 mL for 
Xpert Ultra) actually put the Xpert Ultra at a disadvantage, 
making its performance all the more impressive. The 
added value of cartridge re-engineering is likely to be 
particularly important in paediatric tuberculous 
meningitis, in which volume of CSF is often small.
The Xpert Ultra semi-quantitative results also provide 
evidence of the lower analytical threshold of detection 
playing a role in the assay’s improved performance. Nearly 
half (nine of 21) of samples detected by Xpert Ultra were 
only detected in trace amounts. Of those nine samples, 
only one was positive by Xpert and only two by culture.
Xpert Ultra also showed improved sensitivity compared 
with culture despite similar analytic detection thresholds 
between the two modalities. This difference is most likely 
due to non-viable bacilli being detected by PCR but not 
by culture. In this study, two of 22 participants with 
definite tuberculous meningitis were already on 
pulmonary tuberculous therapy, which probably 
contributed to the presence of non-viable bacilli. Two 
participants had reportedly completed pulmonary 
tuberculous therapy in the past year but had developed 
new meningitis after starting HIV therapy. In the one 
negative Xpert Ultra participant, sample-to-sample 
variation might have resulted in a positive culture and 
negative Xpert Ultra. Centrifugation of samples (>6 mL) 
and testing a larger CSF volume (1–2 mL) with the Xpert 
Ultra cartridge might mitigate this possibility.
Importantly, in the field validation trial of Xpert Ultra 
for pulmonary tuberculosis, investigators found 95·6% 
specificity for the Xpert Ultra and 98·3% specificity for 
Xpert overall.16 This finding was felt to be largely due to 
detection of previously treated antecedent tuberculous 
infection, where, among these patients, the specificity 
was 93·2% for Xpert Ultra and 98·0% for Xpert. Given 
that for tuberculous meningitis, either the mycobacteria 
are cleared or the disease progresses to cause death, this 
cause of lower specificity in pulmonary tuberculous 
should not apply to CSF. Indeed, tuberculous bacilli 
found in the CSF are very unlikely to be due to past 
disease and almost certainly represent tuberculous 
meningitis in this immunocompromised population. 
Additional molecular testing for 14 common meningitis 
aetiologies did not reveal any other explanatory pathogens 
in CSF positive for Xpert Ultra only.18 Furthermore, next-
generation sequencing was able to independently 
confirm M tuberculosis DNA when extracted from six 
stored Ultra-positive cartridges.
Because the study population were all HIV-infected, 
the findings might not be generalisable to people without 
HIV infection. Study limitations include the absence of a 
true gold standard for tuberculous meningitis diagnosis 
and absence of post-mortem examinations.10 In using a 
composite reference standard, incorporation bias is a 
potential concern. Yet, even when excluding the Xpert 
Ultra results, Xpert Ultra had the highest sensitivity for 
definite or probable tuberculous meningitis using the 
consensus clinical case definition.10 Although the Xpert 
Ultra sensitivity was only 70% compared with a case 
definition of probable or definite tuberculous meningitis, 
the case definition is probably imperfect but does provide 
cross-study comparability. Despite these limitations and 
the relatively modest number of tuberculous meningitis 
cases, we believe the principles in this study can be 
extrapolated. Xpert Ultra should be a first-line test for 
tuberculous meningitis after excluding cryptococcal 
infection.
In summary, we tested the performance of Xpert Ultra 
for tuberculous meningitis detection on centrifuged 
CSF. Xpert Ultra showed clearly improved sensitivity 
compared with either Xpert or MGIT culture. Xpert 
Ultra’s combination of lower analytic limit of detection 
and ability to detect dead bacilli after starting tuberculosis 
or HIV therapy vastly improves sensitivity compared 
with either culture or Xpert. Prospective Xpert Ultra 
testing for detection of tuberculous meningitis in a larger 
population is needed to confirm these findings.
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